已核实 DOI PubMed 相关产品: 97

PER-CRISPR/Cas14a system-based electrochemical biosensor for the detection of ctDNA EGFR L858R

Journal 2023 · IF 3.1 · 16(1): 51-61 · 发表于 2023 年 12 月 7 日
作者: Jing Qi,Qianyi Qi,Zhou Zhou,Yixuan Wu,Aiting Cai,Jinran Wu,Bairong Chen,Qingxiang Wang,Lin Chen,Feng Wang
阅读全文 在 PubMed 查看

摘要

The detection of epidermal growth factor receptor (EGFR) mutation L858R in circulating tumor DNA (ctDNA) is beneficial for the clinical diagnosis and personalized therapy of non-small cell lung cancer (NSCLC). Herein, for the first time, the combination of the primer exchange reaction (PER) and clustered regularly interspaced short palindromic repeats (CRISPR) and its associated nucleases (Cas) 14a was used in electrochemical biosensor construction for the detection of ctDNA EGFR L858R. EGFR L858R, as the target, induced the isothermal amplification of the PER reaction, and then the CRISPR/Cas14a system was activated; subsequently, the substrate ssDNA-MB was cleaved and the electron on the surface of the gold electrode transferred, resulting in the fluctuation of the electrochemical redox signal on the electrode surface, whereas the electrochemical signal will be stable when EGFR L858R is absent. Therefore, the concentration of EGFR L858R can be quantified by electrochemical signal analysis. The low detection limit is 0.34 fM and the dynamic detection range is from 1 fM to 1 μM in this work. The PER-CRISPR/Cas14a electrochemical biosensor greatly improved the analytical sensitivity. In addition, this platform also exhibited excellent specificity, reproducibility, stability and good recovery. This study provides an efficient and novel strategy for the detection of ctDNA EGFR L858R, which has great potential for application in the diagnosis and treatment of NSCLC.

本研究中使用的阿拉丁产品

97 款产品在本文中被引用